Vaccination for Meningococcal B (MenB) to combat gonorrhea, as illustrated in this promo material.

Vaccination for Meningococcal B (MenB) to combat gonorrhea, as illustrated in this promo material.

Starting from August 2025, a selective vaccination programme targeting gay, bisexual, and men who have sex with men (GBMSM) at higher risk of gonorrhoea will roll out across the UK. This programme, coordinated by the UK Health Security Agency (UKHSA), will primarily be delivered through specialist sexual health services.

The Meningococcal B vaccine (4CMenB, Bexsero®) will be offered as part of this programme. The vaccine course consists of two doses, each 0.5 ml, administered at least 4 weeks apart, either intramuscularly or subcutaneously. Eligible individuals attending sexual health clinics for bacterial STI testing or treatment should be offered the vaccine during the same visit to ensure timely protection.

It is important to note that the vaccine supply for this programme is centrally purchased by the NHS as part of the national immunisation programme. Ordering of vaccines is done exclusively via the ImmForm system, which is the official NHS digital ordering platform for vaccines in England.

The UKHSA provides a comprehensive range of digital resources for immunisation programmes on its website. These resources include guidance leaflets (product code MGB01EN), posters (product code MGP01), and record cards (product code GON25EN) for the vaccination, all of which are available for order and download.

For those who wish to access these resources, registration and login are required to use the UKHSA's online ordering system. The contact details for the UKHSA are available on their website, and they can also be reached by telephone at 0300 123 1002 or by using the contact form found at https://www.healthpubl...

The use of the 4CMenB vaccine for gonorrhoea is off-label, as it is licensed for meningococcal B disease. However, the Joint Committee on Vaccination and Immunisation (JCVI) has advised this use based on evidence for cross-protection against gonorrhoea in high-risk GBMSM populations.

In conclusion, sexual health providers in the UK intending to vaccinate GBMSM against gonorrhoea with the 4CMenB vaccine must order the vaccine through the NHS ImmForm system, with the programme coordinated by UKHSA and delivered via sexual health clinics participating in the rollout starting August 2025. Additional resources such as guidance leaflets, posters, and record cards for the vaccination can be found and ordered on the UKHSA's website.

Sexual health providers participating in the UK's selective vaccination programme for gay, bisexual, and men who have sex with men (GBMSM) at risk of gonorrhoea, starting from August 2025, can avail the Meningococcal B vaccine (4CMenB, Bexsero®) from the NHS ImmForm system, the official digital ordering platform for vaccines in England. This vaccine, though licensed for meningococcal B disease, is being used off-label for gonorrhoea in high-risk GBMSM populations, based on guidance from the Joint Committee on Vaccination and Immunisation (JCVI).

Read also: